Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy

Current Vascular Pharmacology

Volumn 3, Issue 3, 2005, Pages 267-283

  Obrosova, Irina G ^a   Julius, Ulrich A ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ISOQUINOLINEDIOL; 3 AMINOBENZAMIDE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTHIONINE SULFOXIMINE; BUTYLCRESOL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; FIDARESTAT; GLUTATHIONE; LISINOPRIL; MITOGEN ACTIVATED PROTEIN KINASE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICANARTINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PRIMAQUINE; PROTEIN KINASE C; RUBOXISTAURIN; SALBUTAMOL; SPIRONOLACTONE; TAURINE; THIOCTIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIOXIDANT ACTIVITY; CALCIUM SIGNALING; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; VASCULAR DISEASE;

ANIMALS; DIABETES COMPLICATIONS; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION;

EID: 21644470259     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161054368634     Document Type: Review

References (297)

1. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-9.
2. Stratton I, Adler AI, Neil H, Matthews D, Manley S, Cull C, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
3. Oates P, Mylari B. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs 1999; 8: 2095-2119.
4. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley P. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003; 31: 1423-5.
5. Sheetz M, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-88.
6. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
7. Soldatenkov V, Smulson M. Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology. Int J Cancer (Radiat Oncol Invest) 2000; 90: 59-67.
8. Soriano G, Virag L, Jagtap P, Szabo E, Mabley J, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Med 2001; 7: 108-113.
9. Oei S, Griesenbeck J, Schweiger M. The role of poly(ADP-ribosyl)ation. Rev Physiol Biochem Pharmacol 1997; 131: 127-173.
10. Virag L, Salzman A, Szabo C. Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol 1998; 161: 3753-3759.
11. Virag L, Scott G, Antal-Szalmas P, O'Connor M, Ohshima H, Szabo C. Requirement of intracellular calcium mobilization for peroxynitrite-induced poly(ADP-ribose) synthetase activation and cytotoxicity. Mol Pharmacol 1999; 56: 824-33.
12. Yamanaka H, Pennin C, Willis E, Wasson D, Carson D. Characterization of human poly(ADP-ribose) polymerase with autoantibodies. J Biol Chem 1988; 263: 3879-3883.
13. D'Silva I, Pelletier J, Lagueux J, D'Amours D, Chaudhry M, Weinfeld M, et al. Relative affinities of poly(ADP-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions. Biochem Biophys Acta 1999; 1430: 119-126.
14. Althaus F, Kleczkowska H, Malanga M, Muntener C, Pleschke J, Ebner M, et al. Poly ADP-ribosylation: a DNA break signal mechanism. Mol Cell Biochem 1999; 193: 5-11.
15. Ha H, Hester L, Snyder S. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci USA 2002; 99: 3270-5.
16. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley J, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-13.
17. Obrosova I, Li F, Abatan O, Forsell M, Komjati K, Pacher P, et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004; 53: 711-720.
18. Li F, Szabo C, Pacher P, Southan G, Abatan O, Charniauskaya T, et al. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 2004; 47: 710-7.
19. Minchenko A, Stevens M, White L, Abatan O, Komjati K, Pacher P, et al. Diabetes- induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003; 17: 1514-6.
20. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-57.
21. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27: S79-S83.
22. Strippoli G F, Craig M, Deeks J J, Schena F P, Craig J C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828.
23. Mogensen C E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
24. Nelson R., Knowler W., Pettitt D., Bennett P. Kidney Diseases in Diabetes. In: National Institutes of Diabetes and Digestive and Kidney Diseases, Ed, Diabetes in America. 2nd Edition Bethesda, Maryland, NIH Publication No.95-1468 1995; 349-385.
25. Parving H H, Gall M A, Nielsen F S. Dyslipidaemia and cardiovascular disease in non-insulin-dependent diabetic patients with and without diabetic nephropathy. J Intern Med 1994; 736: 89-94.
26. Yokoyama H, Aoki T, Imahori M, Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004; 66: 448-54..
27. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. Eng J Med 2000; 342: 381-389.
28. Writing team for the Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type-1-diabetes mellitus on development and progression of diabetic nephropathy. - The epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003; 290: 2159-2167.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
30. Mogensen C, Cooper M. Diabetic renal disease: from recent studies to improved clinical practice. Diab Med 2004; 21: 4-17.
31. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complicatons in type 2 diabetes. UKPDS 38. BMJ 1998; 317: 703-713.
32. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997; 40: 1219-1226.
33. Rossing K, Christensen P K, Hovind P, Tarnow L, Rossing P, Parving H H. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66: 1596-605..
34. Cooper M. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972.
35. Wada J, Makino H, Kanwar Y. Gene expression and identification of gene therapy targets in diabetic nephropathy. Kidney Int 2002; 61: 73-78.
36. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguamidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-diabetic rats. Diabetes 1991; 40: 1328-1334.
37. Forbes J, Soulis T, Thallas V, Panagiotopoulos S, Long D, Vasan S, et al. Renoprotective effect of a novel inhibitor of advanced glycation. Diabetologia 2001; 44: 108-114.
38. Koya D, Jirousek M, Lin Y, Ishii H, Kuboki K, King G. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100: 115-126.
39. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-447.
40. Melhem M, Craven P, DeRubertis F. Effects of Dietary Supplementation of alpha-Lipoic Acid on Early Glomerular Injury in Diabetes Mellitus. J Am Soc Nephrol 2001; 12: 124-133.
41. Melhem M, Craven P, Liachenko J, DeRubertis F. alpha-Lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 2002; 13: 108-116.
42. Schleicher E, Weigert C. Role for hexoseamine biosynthetic pathway in diabetic nephropathy. Kidney Int 2000; 58: S13-S18.
43. James L, Fantus I, Goldberg H, Ly H, Scholey J. Overexpression of GFAT activates PAI-1 promoter in mesangial cells. Am J Physiol Renal Physiol 2000; 279: F718-F727.
44. Craven P, Melhem M, Phillips S, DeRubertis F. Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001; 50: 2114-2125.
45. DeRubertis F, Craven P, Melhem M, Salah E. Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interactions. Diabetes 2004; 53: 762-768.
46. Lee H, Yu M, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003; 14: S241-S245.
47. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, et al. Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 2003; 52: 2570-2577.
48. Greene E, Houghton O, Collinsworth G, Garnovskaya M, Nagai T, Sajjad T, et al. 5-HT(2A) receptors stimulate mitogen-activated protein kinase via H(2)O(2) generation in rat renal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F650-F658.
49. Ramachandiran S, Huang Q, Dong J, Lau S, Monks T. Mitogen-activated protein kinases contribute to reactive oxygen species-induced cell death in renal proximal tubule epithelia cells. Chem Res Toxicol 2002; 15: 1635-42.
50. Esposito F, Chirico G, Montesano Gesualdi N, Posadas I, Ammendola R, Russo T, et al. Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase receptor phosphorylation and requires SRC activity. J Biol Chem 2003; 278: 20828-20834.
51. Aiello L, Bursell S, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform selective inhibitor. Diabetes 1997; 46: 1473-1480.
52. Lal M, Brismar H, Eklof A, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002; 61: 2006-2014.
53. Eberhardt W, Beck K, Pfeilschifter J. Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidney Int 2002; 61: 20-30.
54. Montero A, Munger K, Khan R, Valdivielso J, Morrow J, Guasch A, et al. F2-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type 1 diabetes. Kidney Int 2000; 58: 1963-72.
55. Obrosova I, Minchenko A, Marinescu V, Fathallah L, Kennedy A, Stockert C, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001; 44: 1102-10.
56. Caldwell R, Bartoli M, Behzadian M, El-Remessy A, Al-Shabrawey M, Platt D, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-55.
57. Flyvbjerg A, Dagnaes-Hansen F, De Vriese A, Schrijvers B, Tilton R, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-3094.
58. Mifsud S, Kelly D, Qi W, Zhang Y, Pollock C, Wilkinson-Berka J, et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003; 95: 83-91.
59. Saraheimo M, Teppo A, Forsblom C, Fagerudd J, Groop P. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 2003; 46: 1402-1407.
60. Ziyadeh F. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004; 15: S55-S57.
61. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.
62. Dobashi K, Asayama K, Hayashibe H, Uchida N, Kobayashi M, Kawaoi A, et al. Effect of diabetes mellitus induced by streptozotocin on renal superoxide dismutases in the rat. A radioimmunoassay and immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60: 67-72.
63. Schnackenberg C, Wilcox C. The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int 2001; 59: 1859-1864.
64. Obrosova I, Fathallah L, Liu E, Nourooz-Zadeh J. Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid. Free Radic Biol Med 2003; 34: 186-195.
65. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
66. Toborek M, Malecki A, Garrido R, Mattson M, Hennig B, Young B. Arachidonic acid-induced oxidative injury to cultured spinal cord neurons. J Neurochem 1999; 73: 684-692.
67. Yamagishi S, Edelstein D, Du X, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-25100.
68. Kakishita M, Nakamura K, Asanuma M, Morita H, Saito H, Kusano K, et al. Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. J Cardiovasc Pharmacol 2003; 1: S67-S70.
69. Scalera F, Dittrich R, Beckmann M, Beinder E. Effect of endothelin-1 on intracellular glutathione and lipid peroxide availability and on the secretion of vasoactive substances by human umbilical vein endothelial cells. Eur J Clin Invest 2002; 32: 556-562.
70. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care 2002; 5: 561-568.
71. Yan S, Schmidt A, Anderson G, Zhang J, Brett J, Zou Y, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptor/binding proteins. J Biol Chem 1994; 269: 9889-9897.
72. Scivittaro V, Ganz M, Weiss M. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676-F683.
73. Obrosova I, Minchenko A, Vasupuram R, White L, Abatan O, Kumagai A, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor over-expression in streptozotocin-diabetic rats. Diabetes 2003; 52: 864-71.
74. El-Remessy A, Abou-Mohamed G, Caldwell R, Caldwell R. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003; 44: 3135-3143.
75. Inoguchi T, Li P, Umeda F, Yu H, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945.
76. Abiko T, Abiko A, Clermont A, Shoelson B, Horio N, Takahashi J, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003; 52: 829-37.
77. Schmidt A, Yan S, Wautier J, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.
78. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-443.
79. Yim H, Kang S, Hah Y, Chock P, Yim M. Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem 1995; 270: 28228-28233.
80. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest 1996; 97: 1422-1428.
81. Arai K, Maguchi S, Fujii S, Ishibashi H, Oikawa K, Taniguchi N. Glycation and inactivation of human Cu,Zn-superoxuide dismutase. Identification of the in vitro glycated sites. J Biol Chem 1987; 262: 16969-16972.
82. Takata I, Kawamura N, Myint T, Miyazawa N, Suzuki K, Maruyama N, et al. Glycated Cu,Zn-superoxide dismutase in rat lenses: evidence for the presence of fragmentation in vivo. Biochem Biophys Res Com 1996; 219: 243-248.
83. Lee A, Chung S. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999; 13: 23-30.
84. Obrosova I, Fathallah L. Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study. Diabetologia 2000; 43: 1048-1055.
85. Obrosova I, Van Huysen C, Fathallah L, Cao X, Greene D, Stevens M. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002; 16: 123-5.
86. Gupta S, Chough E, Daley J, Oates P, Tornheim K, Ruderman N, et al. Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na+-K+-ATPase activity. Am J Physiol Cell Physiol 2002; 282: C560-6.
87. Song Z, Fu D, Chan Y, Leung S, Chung S, Chung S. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress. Mol Cell Neurosci 2003; 23: 638-647.
88. Kubo E, Urakami T, Fatma N, Akagi Y, Singh D. Polyol pathway-dependent osmotic and oxidative stresses in aldose reductase-mediated apoptosis in human lens epithelial cells: role of AOP2. Biochem Biophys Res Commum 2004; 314: 1050-1056.
89. Obrosova I, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens M, et al. Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications. Diabetes 2005; 54: 234-42.
90. Lal S, Szwergold B, Taylor A, Randall W, Kappler F, Brown T. Production of fructose and fructose-3-phosphate in maturing rat lenses. Invest Ophthalmol Vis Sci 1995; 36: 969-973.
91. Phillips S, Mirrlees D, Thornalley P. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem Pharmacol 1993; 46: 805-811.
92. Niwa T. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl 1999; 731: 23-36.
93. Nagaraj R, Prabhakaram M, Ortwerth B, Monnier V. Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase. Diabetes 1994; 43: 580-586.
94. Tsukushi S, Katsuzaki T, Aoyama I, Takayama F, Miyazaki T, Shimokata K, et al. Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Kidney Int 1999; 55: 1970-1976.
95. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diab Care 2000; 23: 1539-1544.
96. McPherson J, Shilton B, Walton D. Role of fructose in glycation and cross-linking of proteins. Biochemistry 1988; 27: 1901-1907.
97. Keogh R, Dunlop M, Larkins R. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism 1997; 46: 41-47.
98. Ishii H, Tada H, Isogai S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia 1998; 41: 362-364.
99. Nakamura J, Kasuya Y, Hamada Y, Nakashima E, Naruse K, Yasuda Y, et al. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 2001; 44: 480-487.
100. Yamagishi S, Uehara K, Otsuki S, Yagihashi S. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem 2003; 87: 497-507.
101. Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A, et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003; 52: 2603-2614.
102. Han H, Choi H, Park S. High glucose inhibits glucose uptake in renal proximal tubule cells by oxidative stress and protein kinase C. Kidney Int 2000; 57: 918-26.
103. Aruoma O, Halliwell B, Hoey B, Butler J. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J 1988; 256: 251-255.
104. Dekigai H, Murakami M, Kita T. Mechanism of Helicobacter pylori-associated gastric mucosal injury. Digest Dis Sci 1995; 40: 1332-1339.
105. Kilic F, Bhardwaj R, Caufeild J, Trevithick J. Modelling cortical cataractogenesis 22: is in vitro reduction of damage in model diabetic rat cataract by taurine due to its antioxidant activity?. Exp Eye Res 1999; 69: 291-300.
106. Trachtman H, Futterweit S, Maesaka J, Ma C, Valderrama E, Fuchs A, et al. Taurine ameliorates chronic streptozotocin-induced diabetic nephropathy in rats. Am J Physiol 1995; 269: F429-F438.
107. Jerums G, Panagiotopoulos S, Forbes J, Osicka T, Cooper M. Evolving concepts in advanced glycation, diabetic nephropathy and diabetic vascular disease. Arch Biochem Biophys 2003; 419: 55-62.
108. Kim Y, Reddy M, Lanting L, Adler S, Natarajan R. Differential behavior of mesangial cells derived from 12/15-lipooxygenase knockout mice relative to control mice. Kidney Int 2003; 64: 1702-1714.
109. Minchenko A, Stevens M, White L, Abatan O, Szabo C, Obrosova I. Diabetes-induced renal overexpression of endothelin-1 and endothelin A and B receptors is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003; 17: 1514-1516.
110. Yorio T, Krishnamoorthy R, Prasanna G. Endothelin: is it a contributor to glaucoma pathophysiology?. J Glaucoma 2002; 11: 259-270.
111. Chen H C, Guh J Y, Shin S J, Tsai J H, Lai Y H. Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vtvo. J Lab Clin Med 2000; 135: 309-315.
112. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998; 47: 450-456.
113. Arikawa E, Verma S, Dumont A S, McNeill J H. Chronic bosentan treatment improves renal artery vascular function in diabetes. J Hypertens 2001; 19: 803-812.
114. Itoh Y, Nakai A, Kakizawa H, Makino M, Fujiwara K, Kobayashi T, et al. Alteration of endothelin-1 concentration in STZ-induced diabetic rat nephropathy. Effects of a PGI(2) derivative. Horm Res 2001; 56: 165-171.
115. Nakamura T, Ebihara I, Tomino Y, Koide H. Alteration of growth-related proto-oncogene expression in diabetic glomeruli by a specific endothelin receptor A antagonist. Nephrol Dial Transplant 1996; 11: 1528-1531.
116. Skaper S. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection. N Y Acad Sci 2003; 993: 217-28.
117. Ha H. Defective transcription factor activation for proinflammatory gene expression in poly(ADP-ribose) polymerase 1-deficient glia. Proc Natl Acad Sci USA 2004; 101: 5087-5092.
118. Goruppi S, Bonventre J, Kyriakis J. Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 2002; 21: 5427-5436.
119. Brosius F 3. Trophic factors and cytokines in early diabetic glomerulopathy. Exp Diabesity Res 2003; 4: 225-233.
120. Obrosova I, Minchenko A, Frank R, Seigel G, Zsengeller Z, Pacher P, et al. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med 2004; 14: 55-64.
121. Onozaki A, Midorikawa S, Sanada H, Hayashi Y, Baba T, Katoh T. et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. Biochem Biophys Res Commun 2004; 317: 24-29.
122. Khamaisi M, Schrijvers B, De Vriese A, Raz I, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003; 18: 1427-1430.
123. Freeburg P, Robert B, St John P, Abrahamson D. Podocyte expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc Nephrol 2003; 14: 927-38.
124. Kanellis J, Levidiotis V, Khong T, Cox A, Slacker S, Gilbert R, et al. A study of VEGF and its receptors in two rat models of proteinuria. Nephron Physiol 2004; 96: P26-P36.
125. de Vriese A, Tilton R, Elger M, Stephan C, Kriz W, Lameire N. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
126. Barnett A H, Bain S C, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
127. Cooper M, Boner G. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabet Med 2004; 21 Suppl 1: 15-8.
128. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-5.
129. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In: Dyck, PJ Ed, Peripheral neuropathy. Philadelphia, W. B. Saunders 1993; 1219-1250.
130. National Institutes of Diabetes and Digestive and Kidney Diseases Ed, Diabetes in America. 2nd Edition Bethesda, Maryland, NIH Publication No.95-1468, 1995.
131. Calcutt N. Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol 2002; 50: 205-28.
132. Boulton A. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-1353.
133. Gordois A, Scuffham P, Shearer A. The health care costs of diabetic peripheral neuropathy in the U.S.. Diabetes Care 2003; 26: 1790-1795.
134. Jermendy G. Clinical consequences of cardiovascular autonomic neuropathy in diabetic patients. Acta Diabetol 2003; 40 Suppl 2: S370-4..
135. Haslbeck M. Autonomic neuropathies in diabetes mellitus: diagnosis - therapy - risks. Z Gesamte Inn Med 1993; 48: 162-176.
136. Gerritsen J, Dekker J M, TenVoorde B J, Kostense P J, Heine R J, Bouter L M, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension. or a history of cardiovascular disease. The Hoorn Study. Diabetes Care 2001; 24: 1793-1798.
137. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995; 122: 561-568.
138. Boulton A. Lowering the risk of neuropathy, foot ulcers and amputations. Diab Medicine 1998; 15 (Suppl.4): S57-S59.
139. Donaghue K. Autonomic neuropathy: diagnosis and impact on health in adolescents with diabetes. Horm Res 1998; 50 (Suppl.1): 33-37.
140. Low P, Nickander K. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991; 40: 873-877.
141. Kihara N, Schmelzer J, Poduslo J, Curran F, Nickander K, Low P. Aminoguanidine effect on nerve blood flow, vascular permeability, electro-physiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-6111.
142. Cameron N, Cotter M, Archibald V, Dines K, Maxfield E. Antioxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rat. Diabetologia 1994; 37: 449-459.
143. Nagamatsu M, Nickander K, Schmelzer J, Raya A, Wittrock D, Tritschler H, et al. Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy. Diabetes Care 1995; 18: 1160-1167.
144. Karasu C, Dewhurst M, Stevens E, Tomlinson D. Effects of antioxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids. Diabetologia 1995; 38: 129-134.
145. Low P, Nickander K, Tritschler H. The Roles of Oxidative Stress and Antioxidant Treatment in Experimental Diabetic Neuropathy. Diabetes 1997; 46 (Suppl. 2): 38S-42S.
146. Cotter M, Cameron N. Effects of dietary supplementation with arachidonic acid rich oils on nerve conduction and blood flow in streptozotocin-diabetic rats. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 337-343.
147. Cameron N, Tuck Z, McCabe L, Cotter M. Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 2001; 44: 1161-1169.
148. Cameron N, Cotter M, Jack A, Basso M, Hohman T. Protein kinase C effects on nerve function, perfusion, Na(+),K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999; 42: 1120-1130.
149. Obrosova I, Van Huysen C, Fathallah L, Cao X, Stevens M, Greene D. Evaluation of a1-adrenoceptor antagonist on nerve function, metabolism and antioxidative defense. FASEB J 2000; 14: 1548-1558.
150. Stevens M O I, Cao X, Van Huysen C, Greene D. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006-1015.
151. Cameron N, Cotter M, Basso M, Hohman T. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction, and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997; 40: 271-281.
152. Coppey L, Gellett J, Davidson E, Dunlap J, Lund D, Yorek M. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-1937.
153. Coppey L, Gellett J, Davidson E, Yorek M. Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 2003; 37: 33-40.
154. Yorek M. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 2003; 37: 471-480.
155. Kinoshita J, Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 1988; 4: 323-337.
156. Kador P. The role of aldose reductase in the development of diabetic complications. Med Res Rev 1988; 8: 325-352.
157. Suzuki E, Yasuda K, Yasuda K, Miyazaki S, Takeda N, Inouye H, et al. IH-NMR analysis of nerve edema in the streptozotocin-induced diabetic rat. J Lab Clin Med 1994; 124: 627-637.
158. Greene D, Sima A, Stevens M, Feldman E, Lattimer S. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992; 15: 1902-1925.
159. Sima A, Dunlap J, Davidson E, Wiese T, Lightle R, Greene D, et al. Supplemental myo-inositol prevents L-fucose-induced diabetic neuropathy. Diabetes 1997; 46: 301-306.
160. Stevens M, Dananberg J, Feldman E, Lattimer S, Kamijo M, Thomas T, et al. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94: 853-859.
161. Williamson J, Chang K, Frangos M, Hasan K, Ido Y, Kawamura T, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813.
162. Doss D, Kuruvilla R, Bianchi R, Peterson R, Eichberg J. Effects of hypoxia and severity of diabetes on Na,K-ATPase activity and arachidonoyl-containing molecular species in streptozotocin-diabetic rat nerve. J Periph Nerv Syst 1997; 2: 1-9.
163. Kuruvilla R, Eichberg J. Depletion of phospholipid arachidonoyl-containing molecular species in a human Schwann cell line grown in elevated glucose and their restoration by an aldose reductase inhibitor. J Neurochem 1998; 71: 775-783.
164. Sima A, Ristic H, Merry A, Kamijo M, Lattimer S, Stevens M, et al. Primary preventive and secondary interven-tionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996; 97: 1900-1907.
165. Fernyhough P, Brewster W, Fernandes K, Diemel L, Tomlinson D. Stimulation of nerve growth-factor and substance P expression in the iris-trigeminal axis of diabetic rats - involvement of oxidative stress and effects of aldose reductase inhibition. Brain Res 1998; 802: 247-253.
166. Zhuang H, Snyder C, Pu S, Ishii D. Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp Neurol 1996; 140: 198-205.
167. Zhuang H, Wuarin L, Fei Z, Ishii D. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J Pharmacol Exp Ther 1997; 283: 366-74.
168. Mizisin A, Bache M, DiStefano P, Acheson A, Lindsay R, Calcutt N. BDNF attenuates functional and structural disorders in nerves of galactose-fed rats. J Neuropathol Exp Neurol 1997; 56: 1290-1301.
169. Mizisin A, Steinhardt R, O'Brien J, Calcutt N. TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in galactose-fed rats. J Neuropathol Exp Neurol 2001; 60: 953-960.
170. Sayers N, Beswick L, Middlemas A, Calcutt N, Mizisin A, Tomlinson D, et al. Neuro-trophin-3 prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats. Diabetes 2003; 52: 2372-2380.
171. Huang T, Price S, Chilton L, Calcutt N, Tomlinson D, Verkhratsky A, et al. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 2003; 52: 2129-2136.
172. Mizisin A, Vu Y, Shuff M, Calcutt N. Ciliary neurotrophic factor improves nerve conduction and ameliorates regeneration deficits in diabetic rats. Diabetes 2004; 53: 1807-1812.
173. Fernyhough P, Gallagher A, Averill S, Priestley J, Hounsom L, Patel J, et al. Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 1999; 48: 881-889.
174. Purves T, Middlemas A, Agthong S, Jude E, Boulton A, Fernyhough P, et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001; 15: 2508-2514.
175. Price S, Agthong S, Middlemas A, Tomlinson D. Mitogen-Activated Protein Kinase p38 Mediates Reduced Nerve Conduction Velocity in Experimental Diabetic Neuropathy: Interactions With Aldose Reductase. Diabetes 2004; 53: 1851-1856.
176. Greene D, Stevens M, Obrosova I, Feldman E. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999; 375: 217-223.
177. Srinivasan S, Stevens M, Wiley J. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 2000; 49: 1932-1938.
178. Schmeichel A, Schmelzer J, Low P. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003; 52: 165-171.
179. Schmidt R, Plurad S, Coleman B, Williamson J, Tilton R. Effects of sorbinil, dietary myo-inositol supplementation, and insulin on resolution of neuroaxonal dystrophy in mesenteric nerves of streptozocin-induced diabetic rats. Diabetes 1991; 40: 574-82.
180. Schmid H, Forman L, Cao X, Sherman P, Stevens M. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999; 48: 603-8.
181. Keegan A, Jack A, Cotter M, Cameron N. Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats. J Cardiovasc Pharmacol 2000; 35: 606-13.
182. Naugle M, Cotter M, Cameron N. Protein kinase C beta inhibition and aorta and corpus cavernosum function in streptozotocin-diabetic mice. Eur J Pharmacol 2003; 475: 99-106.
183. Schmidt R, Dorsey D, Beaudet L, Peterson R. Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy. Am J Pathol 2003; 163: 21-8.
184. Nangle M, Cotter M, Cameron N. Effects of the peroxynitrite decomposition catalyst, FeTMPyP, on function of corpus cavernosum from diabetic mice. Eur J Pharmacol 2004; 502: 143-8.
185. Ametov A, Barinov A, Dyck P, Hermann R, Kozlova N, Litchy W, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770-776.
186. Ziegler D, Nowak H, Kempler P, Vargha P, Low P. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med 2004; 21: 114-121.
187. Bravenboer B, Kappelle A, Hamers F, van Buren T, Erkelens D, Gispen W. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia 1992; 35: 813-814.
188. Nishikawa T, Edelstein D, Du X, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404(6779): 787-790.
189. Cheng C, Zochodne D. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 2003; 52: 2363-71.
190. Obrosova I, Fathallah L, Stevens M. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neurol 2001; 172: 211-219.
191. Obrosova I. Update on the pathogenesis of diabetic neuropathy. Curr Diab Rep 2003; 3: 439-445.
192. Obrosova I, Mabley J, Zsengeller Z, Charniauskaya T, Abatan O, Szabo C. Role for Nitrosative Stress in diabetic Neuropathy: Evidence from Studies with a Peroxynitrite Decomposition Catalyst. Diabetes 2004; 53(Suppl.2): A33.
193. Hoeldtke, R, Bryner K, McNeill D, Hobbs G, Riggs J, Warehime S, et al. Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes 2002; 51: 2817-2825.
194. Packer L, Witt E, Tritschler H. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-250.
195. Maitra I, Serbinova E, Tritschler H, Packer L. Stereospecific effects of alpha-lipoic acid on buthionine sulfoximine-induced cataract formation in newborn rats. Biochem Biophys Res Commun 1996; 221: 422-429.
196. Cameron N, Cotter M, Maxfield E. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993; 36: 299-304.
197. Coppey L, Gellett J, Davidson E, Dunlap J, Lund D, Salvemini D, et al. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 2001; 134: 21-29.
198. Cameron N, Jack A, Cotter M. Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001; 31: 125-135.
199. Pertovaara A, Wei H, Kalmari J, Ruotsalainen M. Pain behavior and response properties of spinal dorsal horn neurons, following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp Neurol 2001; 167: 425-434.
200. a Calcutt N. Experimental models of painful diabetic neuropathy. J Neurol Sci 2004; 220: 137-139.
201. b Calcutt N. Modeling diabetic sensory neuropathy in rats. Methods Mol Med 2004; 99: 55-65.
202. Calcutt N, Freshwater J, Mizisin A. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 2004; 47: 718-724.
203. Obrosova I. How does glucose generate oxidative stress in peripheral nerve?. Int Rev Neurobiol 2002; 50: 3-35.
204. Pop-Busui R, Sullivan K, Van Huysen C, Bayer L, Cao X, Towns R, et al. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits. Exp Neurol 2001; 168: 259-272.
205. Obrosova I, Cao X, Greene D, Stevens M. Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL-alpha-lipoic acid. Diabetologia 1998; 41: 1442-1450.
206. Obrosova I, Stevens M. Effect of dietary taurine supplementation on GSH and NAD(P)-redox status, lipid peroxidation, and energy metabolism in diabetic precataractous lens. Invest Ophthalmol Vis Sci 1999; 40: 680-688.
207. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene D, et al. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 2002; 51: 2619-28.
208. Hounsom L, Corder R, Patel J, Tomlinson D. Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy. Diabetologia 2001; 44: 424-428.
209. Sagara M, Satoh J, Wada R, Yagihashi S, Takahashi K, Fukuzawa M, et al. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 1996; 39: 263-269.
210. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski A, Quist W, et al. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 2002; 106: 2680-6.
211. Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, et al. TNF-alpha expression in painful and nonpainful neuropathies. Neurology 2001; 56: 1371-1377.
212. Svensson C, Marsala M, Westerlund A, Calcutt N, Campana W, Freshwater J, et al. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 2003; 86: 1534-1544.
213. Wallace M. Calcium and sodium channel antagonists for the treatment of pain. Clin J Pain 2000; 16(Suppl. 2): S80-S85.
214. Scott G, Kean R, Mikheeva T, Fabis M, Mabley J, Szabo C, et al. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther 2004; 310: 1053-1061.
215. Veres B, Radnai B, Gallyas F, Varbiro G, Berente Z, Osz E, et al. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) inflammation in mice. J Pharmacol Exp Ther 2004; 310: 247-255.
216. Aarts M, Tymianski M. Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. Cur Mol Med 2004; 4: 137-147.
217. Kempen J, O'Colmain B, Leske M, Haffner S, Klein R, Moss S, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-63.
218. Klein R, Klein B E, Moss S E, Davis M. D., DeMets D L. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
219. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
220. Chan W C, Lim L T, Quinn M J, Knox F A, McCance D, Best R M. Management and outcome of sight-threatening diabetic retinopathy in pregnancy. Eye 2004; 18: 826-32.
221. Lyons T J, Jenkins A J, Zheng D, Lackland D T, McGee D, Garvey W T, Klein R L. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-8.
222. Gaede P, Vedel P, Larsen N, Jensen G V, Parving H H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
223. Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 2003; 17: 374-9.
224. Dagher Z, Park Y, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004; 53: 2404-11.
225. Kador P, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita J. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophtahlmol 1990; 108: 1301-1309.
226. Neuenschwander H, Takahashi Y, Kador P. Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J Ocul Pharmacol Ther 1997; 13: 517-528.
227. Robison W J, Jacot J, Glover J, Basso M, Hohman T. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats. Invest Ophthalmol Vis Sci 1998; 39: 1933-1941.
228. Kern T, Engerman R. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res 1994; 13: 863-867.
229. Kador P, Takahashi Y, Wyman M, Ferris F 3. Diabeteslike proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1995; 113: 352-354.
230. Frank R, Amin R, Kennedy A, Hohman T. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol 1997; 115: 1036-47.
231. Kobayashi T, Kubo E, Takahashi Y, Kasahara T, Yonezawa H, Akagi Y. Retinal vessel changes in galactose-fed dogs. Arch Ophthalmol 1998; 116: 785-9.
232. Cruz J, Oliveira M, Hohman T, Fortes Z. Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2000; 391: 163-74.
233. Amano S, Yamagishi S, Kato N, Inagaki Y, Okamoto T, Makino M, et al. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem Biophys Res Commun 2002; 299: 183-188.
234. Lou M, Dickerson J J, Garadi R, York B J. Glutathione depletion in the lens of galactosemic and diabetic rats. Exp Eye Res 1988; 46: 517-530.
235. Kador P. The contributions of Jin H. Kinoshita to aldose reductase research. Exp Eye Res 1990; 50: 615-620.
236. Obrosova I, Stevens M, Lang H. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 2001; 62: 172-180.
237. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003; 52: 506-511.
238. Murata M, Ohta N, Fujisawa S, Tsai J, Sato S, Akagi Y, et al. Selective pericyte degeneration in the retinal capillaries of galactose-fed dogs results from apoptosis linked to aldose reductase-catalyzed galactitol accumulation. J Diabetes Complications 2002; 16: 363-70.
239. Miwa K, Nakamura J, Hamada Y, Naruse K, Nakashima. E, Kato K, et al. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 2003; 60: 1-9.
240. a Hammes H, Strodter D, Weiss A, Bretzel R, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995; 38: 656-660.
241. b Hammes H, Ali S, Uhlmann M, Weiss A, Federlin K, Geisen K, et al. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia 1995; 38: 269-273.
242. Kunisaki M, Bursell S, Umeda F, Nawata H, King G. Prevention of diabetes-induced abnormal retinal blood flow by treatment with d-alpha-tocopherol. Biofactors 1998; 7: 55-67.
243. Bursell S, Takagi C, Clermont A, Takagi H, Mori F, Ishii H, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997; 38: 2711-2720.
244. Poulaki V, Qin W, Joussen A, Hurlbut P, Wiegand S, Rudge J, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 2002; 109: 805-15.
245. Chou E, Suzuma, I, Way K, Opland D, Clermont A, Naruse K, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 200; 105: 373-9.
246. Hammes H, Bartmann A, Engel L, Wulfroth P. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 1997; 40: 629-34.
247. Ansari N, Zhang W, Fulep E. Prevention of pericyte loss by trolox in diabetic rat retina. J Toxicol Environ Health 1998; 54: 467-475.
248. Kowluru R, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004; 53: 3233-8.
249. Lightman S, Rechthand E, Teribayashi H, Palestine A, Rapoport S, Kador P. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors. Diabetes 1987; 36: 1271-1275.
250. Vinores S, McGehee R, Lee A, Gadegbeku C, Campochiaro P. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats. J Histochem Cytochem 1990; 38: 1341-1352.
251. Aukunuru J, Sunkara G, Ayalasomayajula S, DeRuiter J, Clark R, Kompella U. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res 2002; 19: 278-85.
252. Koya D, King G. Protein Kinase C activation and development of diabetic complications. Diabetes 1998; 47: 859-866.
253. Kern T, Tang J, Mizutani M, Kowluru R, Nagaraj R, Romeo G, et al. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 2000; 41: 3972-8.
254. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003; 14(Suppl 3): S227-S232.
255. Nishida T, Nakagawa S, Manabe R. Superoxide dismutase activity in diabetic rat retina. Jpn J Ophthalmol 1984; 28: 377-382.
256. Simonelli F, Cotticelli L, Pensa M, Teramo P, Acampora A, Rinaldi E. Lipid peroxidation and cataract formation in experimental diabetes. Boll Soc Ital Biol Sper 1989; 65: 759-765.
257. Kowluru R, Kern T, Engerman R, Armstrong D. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 1996; 45: 1233-1237.
258. Obrosova I, Fathallah L, Greene D. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Eur J Pharmacol 2000; 398: 139-46.
259. Agardh C, Agardh E, Qian Y, Hultberg B. Glutathione levels are reduced in diabetic rat retina but are not influenced by ischemia followed by recirculation. Metabolism 1998; 47: 269-272.
260. Fathallah L, Obrosova I. Increased Retinal Lipid Peroxidation in Early Diabetes is not Associated with Ascorbate Depletion or Changes in Ascorbate Redox State. Exp Eye Res 2001; 72: 719-23.
261. Kowluru R, Kern T, Engerman R. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IY. Antioxidant defense system. Free Rad Biol Med 1997; 22: 587-592.
262. Erdelmeier I, Gerard-Monnier D, Yadan J, Chaudiere J. Reactions of N-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem Res Toxicol 1998; 11: 1184-1194.
263. Srivastava S, Chandra A, Wang L, Seifert W J, DaGue B, Ansari N, et al. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart. J Biol Chem 1998; 273: 10893-10900.
264. Hartley D, Kroll D, Petersen D. Prooxidant-initiated lipid peroxidation in isolated rat hepatocytes: detection of 4-hydroxynonenal- and malondialdehyde-protein adducts. Chem Res Toxicol 1997; 10: 895-905.
265. Scott B, Aruoma O, Evans P, O'Neill C, Van der Vliet A, Cross C, et al. Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Rad Res 1994; 20: 119-123.
266. Block F, Schwartz M. Effects of antioxidants on ischemic retinal dysfunction. Exp Eye Res 1997; 64: 559-564.
267. Kowluru R, Koppolu P, Chakrabarti S, Chen S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 2003; 37: 1169-80.
268. Kowluru R, Tang J, Kern T. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001; 50: 1938-42.
269. Di Leo M, Ghirlanda G, Gentiloni Silveri N, Giardina B, Franconi F, Santini S. Potential therapeutic effect of antioxidants in experimental diabetic retina: a comparison between chronic taurine and vitamin E plus selenium supplementations. Free Radic Res 2003; 37: 323-30.
270. Ellis E, Guberski D, Somogyi-Mann M, Grant M. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/W or diabetic rat. Free Radic Biol Med 2000; 28: 91-101.
271. Nespereira B, Perez-Ilzarbe M, Fernandez P, Fuentes A, Paramo J, Rodriguez J. Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. Atherosclerosis 2003; 171: 67-73.
272. El-Remessy A, Behzadian M, Abou-Mohamed G, Franklin T, Caldwell R, Caldwell R. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162: 1995-2004.
273. Khatri J, Johnson C, Magid R, Lessner S, Laude K, Dikalov S, et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004; 109: 520-5.
274. Ferrara N, Houck K, Jakeman L, Winer J, Leung D. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211-218.
275. Adamis A, Shima D, Yeo K-T, Yeo T, Brown L, Berse B, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993; 193: 631-638.
276. Aiello L, Northrup J, Keyt B, Takagi H, Iwamoto M. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-1544.
277. Amin R, Frank R, Kennedy A, Eliott D, Puklin J, Abrams G. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 36-47.
278. Gerhardinger C, Brown L, Roy S, Mizutani M, Zucker C, Lorenzi M. Expression of vascular endothelial frowth factor in the human retina and in non-proliferative diabetic retinopathy. Am J Pathol 1998; 152: 1453-1462.
279. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-4787.
280. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-1028.
281. Aiello L. Vascular Endothelial Growth Factor and the Eye: Biochemical Mechanisms of Action and Implications for Novel Therapeutics. Ophthalmic Res 1997; 29: 354-362.
282. Senger D, Galli S, Dvorak A, Perruzzi C, Harvey V, Dvorak. HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
283. Leung D, Cachianes G, Kunang W, Goeddel D, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
284. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101: 1219-1224.
285. Kuroki M, Voest E, Amano S, Beerepoot L, Takashima S, Tolentino M, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667-1675.
286. Rota R, Chiavaroli C, Garay R, Hannaert P. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004; 495: 217-24.
287. MeBain V, Robertson M, Muckersie E, Forrester J, Knott R. High glucose concentration decreases insulin-like growth factor type 1-mediated mitogen-activated protein kinase activation in bovine retinal endothelial cells. Metabolism 2003; 52: 547-51.
288. Du Y, Sarthy V, Kern T. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R735-41.
289. Joussen A, Poulaki V, Le M, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450-2.
290. Cukiernik M, Hileeto D, Evans T, Mukherjee S, Downey D, Chakrabarti S. Vascular endothelial growth factor in diabetes induced early retinal abnormalities. Diabetes Res Clin Pract 2004; 65: 197-208.
291. Zheng L, Szabo C, Kern T. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004; 53: 2960-7.
292. Mizutani M, Kern T, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97: 2883-2890.
293. Sugawara R, Hikichi T, Kitaya N, Mori F, Nagaoka T, Yoshida A, et al. Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr Eye Res 2004; 29: 11-6.
294. Frank R. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002; 133: 693-8.
295. Aiello L, Gardner T, King G, Blankenship G, Cavallerano J, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 1998; 21: 143-156.
296. Frank R. Diabetic retinopathy. N Eng J Med 2004; 350: 48-58
297. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, Szabo C. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J. 2005; 19: 401-403.